glp 1 addiction trials GLP-1s Like Ozempic May Be a New Treatment for GLP-1 therapy appears to reduce
Description
Clinical Update 9/29/2025 TUDCA for Boosting GLP-1
Regulatory nods for Wegovy in Mexico and Brazil widen eligibility to millions of high-BMI adults, while cardiovascular-outcome data support use in secondary prevention
The study by Tao et al
Clinical Evidence and Patient Outcomes: What Research Shows Recent GLP-1 trials document reflux as an adverse event in 515% of participants, though severity varies widely
Low Risk of Hypoglycemia : Unlike some other diabetes medications, semaglutide carries a low risk of causing hypoglycemia (low blood sugar), especially when not used with insulin or sulfonylureas
